Table 2.
Characteristics and Follow-up of Patients with Transmitted Drug Resistancea
| |
|
CD4 cell count (cells/ml) |
PVL (copies/ml) |
|
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient | Mutation(s) | Initial | 6-month | 1-year | 2-year | Initial | 6-month | 1-year | 2-year | Treatment history |
| ID3 | D67N, K103N, K238T | 421 | 361 | 608 | 707 | 14396 | 22453 | <75 | <75 | Started on EFV/TDF/FTC at 6 months, continues on this medication |
| ID11 | K103N | 144 | 253 | 240 | 464 | 72189 | <75 | <75 | <75 | Started on EFV/TDF/FTC initially, changed to FOS/ TDF/FTC 1 month later |
| ID17 | K103N | 252 | 440 | 434 | 448 | 80935 | <75 | <75 | <75 | Started on LPV/RTV/TDF/FTC because partners had K103N |
| ID27 | K103N | 142 | 246 | 180 | 336 | 105198 | <75 | <75 | <50 | Started on EFV/TDF/FTC initially, changed to LPV/RTV/TDF/FTC 1 week later |
| ID31 | M46I | 812 | Unavailable | 980 | 443 | 17250 | Unavailable | 546 | 14505 | Started on LPV/RTV/TDF/FTC through ACTG trial, stopped after 9 months |
| ID32 | K103N | 677 | Unavailable | 362 | Unavailable | 311524 | Unavailable | 119740 | Unavailable | No medications initially, lost to follow-up |
| ID33 | K103N | 16 | Unavailable | Unavailable | Unavailable | 38420 | Unavailable | Unavailable | Unavailable | Started on EFV/TDF/FTC initially, lost to follow-up |
a
ACTG, AIDS Clinical Trial Group; EFV, efavirenz; TDF, tenofovir; FTC, emtricitabine; FOS, fosamprenavir; LPV/RTV, lopinavir and ritonavir.